A175250 Stock Overview
A biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Icure Pharmaceutical Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,953.00 |
| 52 Week High | ₩3,490.00 |
| 52 Week Low | ₩1,660.00 |
| Beta | 1.04 |
| 1 Month Change | 0.62% |
| 3 Month Change | -4.03% |
| 1 Year Change | -6.78% |
| 3 Year Change | -87.60% |
| 5 Year Change | -83.55% |
| Change since IPO | -90.72% |
Recent News & Updates
Does Icure Pharmaceutical Incorporation (KOSDAQ:175250) Have A Healthy Balance Sheet?
Dec 09
Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Sep 04Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?
Aug 28What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You
Jul 21Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
May 31Recent updates
Does Icure Pharmaceutical Incorporation (KOSDAQ:175250) Have A Healthy Balance Sheet?
Dec 09Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Sep 04Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?
Aug 28What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You
Jul 21Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
May 31Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?
May 27Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio
Mar 07We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt
Dec 25
Shareholder Returns
| A175250 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | -9.0% | -4.1% | -3.7% |
| 1Y | -6.8% | -11.5% | -10.4% |
Return vs Industry: A175250 exceeded the KR Personal Products industry which returned -11.5% over the past year.
Return vs Market: A175250 exceeded the KR Market which returned -10.4% over the past year.
Price Volatility
| A175250 volatility | |
|---|---|
| A175250 Average Weekly Movement | 11.7% |
| Personal Products Industry Average Movement | 7.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A175250's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A175250's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 218 | n/a | www.icure.co.kr |
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks.
Icure Pharmaceutical Incorporation Fundamentals Summary
| A175250 fundamental statistics | |
|---|---|
| Market cap | ₩72.98b |
| Earnings (TTM) | ₩521.32m |
| Revenue (TTM) | ₩60.61b |
140.0x
P/E Ratio1.2x
P/S RatioIs A175250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A175250 income statement (TTM) | |
|---|---|
| Revenue | ₩60.61b |
| Cost of Revenue | ₩56.16b |
| Gross Profit | ₩4.45b |
| Other Expenses | ₩3.93b |
| Earnings | ₩521.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.95 |
| Gross Margin | 7.34% |
| Net Profit Margin | 0.86% |
| Debt/Equity Ratio | 44.7% |
How did A175250 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 09:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Icure Pharmaceutical Incorporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Choongwoo Seo | SK Securities Co., Ltd. |